Company’s 36-month beta value is 1.26.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCDA is 2.36M, and currently, short sellers hold a 77.50% ratio of that floaft. The average trading volume of BCDA on September 23, 2024 was 827.79K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BCDA) stock’s latest price update
The stock price of BioCardia Inc. (NASDAQ: BCDA) has dropped by -14.77 compared to previous close of 2.98. Despite this, the company has seen a fall of -14.48% in its stock price over the last five trading days. globenewswire.com reported 2024-09-18 that SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024.
BCDA’s Market Performance
BCDA’s stock has fallen by -14.48% in the past week, with a monthly drop of -12.41% and a quarterly drop of -15.33%. The volatility ratio for the week is 12.74% while the volatility levels for the last 30 days are 18.37% for BioCardia Inc. The simple moving average for the past 20 days is -7.77% for BCDA’s stock, with a -53.75% simple moving average for the past 200 days.
BCDA Trading at -12.11% from the 50-Day Moving Average
After a stumble in the market that brought BCDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.08% of loss for the given period.
Volatility was left at 18.37%, however, over the last 30 days, the volatility rate increased by 12.74%, as shares sank -5.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.72% lower at present.
During the last 5 trading sessions, BCDA fell by -14.48%, which changed the moving average for the period of 200-days by -73.16% in comparison to the 20-day moving average, which settled at $2.75. In addition, BioCardia Inc. saw -74.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCDA starting from Altman Peter, who purchase 300 shares at the price of $3.05 back on Jul 01 ’24. After this action, Altman Peter now owns 39,745 shares of BioCardia Inc., valued at $915 using the latest closing price.
Altman Peter, the President and CEO of BioCardia Inc., purchase 200 shares at $2.99 during a trade that took place back on Jun 28 ’24, which means that Altman Peter is holding 39,445 shares at $598 based on the most recent closing price.
Stock Fundamentals for BCDA
Current profitability levels for the company are sitting at:
- -20.05 for the present operating margin
- 0.02 for the gross margin
The net margin for BioCardia Inc. stands at -20.0. The total capital return value is set at 7.27. Equity return is now at value -703.62, with -184.48 for asset returns.
Based on BioCardia Inc. (BCDA), the company’s capital structure generated -1.38 points at debt to capital in total, while cash flow to debt ratio is standing at -6.24. The debt to equity ratio resting at -0.58. The interest coverage ratio of the stock is -953.56.
Currently, EBITDA for the company is -11.23 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 20.12. The receivables turnover for the company is 42.8for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In a nutshell, BioCardia Inc. (BCDA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
